Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Nicholson

Showing results (331-340 of 357) with videos related to

Pageof 36
Sort By:
Plos One|July 19, 2012
Tamoxifen-induced epigenetic silencing of oestrogen-regulated genes in anti-hormone resistant breast cancerAndrew Stone, Fatima Valdés-Mora, Julia M W Gee, et al.
Endocrine-Related Cancer|September 7, 2006
Phosphorylation of ERalpha at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERalpha phosphorylation in breast cancer progressionN Sarwar, J-S Kim, J Jiang, et al.
Cancer Research|September 18, 2001
Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancerJ F Robertson, R I Nicholson, N J Bundred, et al.
British Journal of Cancer|October 14, 2004
Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinomaD M Abd El-Rehim, S E Pinder, C E Paish, et al.
British Journal of Cancer|November 2, 2013
Role of endoplasmic reticulum stress induction by the plant toxin, persin, in overcoming resistance to the apoptotic effects of tamoxifen in human breast cancer cellsR A McCloy, E J Shelley, C G Roberts, et al.
British Journal of Cancer|July 1, 1996
C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicatorsA Travis, S E Pinder, J F Robertson, et al.
Hormone Molecular Biology and Clinical Investigation|May 12, 2015
Antihormone induced compensatory signalling in breast cancer: an adverse event in the development of endocrine resistanceJulia M W Gee, Robert I Nicholson, Denise Barrow, et al.
Histopathology|March 16, 2002
Neuroendocrine differentiation and prognosis in breast adenocarcinomaA Miremadi, S E Pinder, A H S Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2007
Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotypeEmad A Rakha, Maysa E El-Sayed, Andrew R Green, et al.
Breast Cancer Research and Treatment|January 31, 2012
Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II studyIrene Kuter, Julia M W Gee, Roberto Hegg, et al.
Pageof 36

Showing results (331-340 of 357) with videos related to

Sort By:
Pageof 36
Plos One|July 19, 2012
Tamoxifen-induced epigenetic silencing of oestrogen-regulated genes in anti-hormone resistant breast cancerAndrew Stone, Fatima Valdés-Mora, Julia M W Gee, et al.
Endocrine-Related Cancer|September 7, 2006
Phosphorylation of ERalpha at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERalpha phosphorylation in breast cancer progressionN Sarwar, J-S Kim, J Jiang, et al.
Cancer Research|September 18, 2001
Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancerJ F Robertson, R I Nicholson, N J Bundred, et al.
British Journal of Cancer|October 14, 2004
Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinomaD M Abd El-Rehim, S E Pinder, C E Paish, et al.
British Journal of Cancer|November 2, 2013
Role of endoplasmic reticulum stress induction by the plant toxin, persin, in overcoming resistance to the apoptotic effects of tamoxifen in human breast cancer cellsR A McCloy, E J Shelley, C G Roberts, et al.
British Journal of Cancer|July 1, 1996
C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicatorsA Travis, S E Pinder, J F Robertson, et al.
Hormone Molecular Biology and Clinical Investigation|May 12, 2015
Antihormone induced compensatory signalling in breast cancer: an adverse event in the development of endocrine resistanceJulia M W Gee, Robert I Nicholson, Denise Barrow, et al.
Histopathology|March 16, 2002
Neuroendocrine differentiation and prognosis in breast adenocarcinomaA Miremadi, S E Pinder, A H S Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2007
Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotypeEmad A Rakha, Maysa E El-Sayed, Andrew R Green, et al.
Breast Cancer Research and Treatment|January 31, 2012
Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II studyIrene Kuter, Julia M W Gee, Roberto Hegg, et al.
Pageof 36